Health plans and insurers are not yet turning to biosimilar infliximab as a preferred therapy, according to Gillian Woollett, DPhil, MA, of Avalere. Her new report surveyed publicly available policy about health plans across the nation. The principal finding was that step therapy was commonly used to encourage use of the originator product. In fact, … Continue reading Plans Use Step Therapy to Encourage Utilization of Remicade Over Biosimilars
Tag: rheumatoid arthritis
Rituximab and Filgrastim Biosimilars Being Reviewed by FDA
Sandoz's Rituximab and Adello Biologic' Filgrastim Biosimilars Submitted to FDA
Is the Biologic Me-too Era Different?
In the biologic category, the biosimilars Inflectra®, AmjevitaTM, ErelziTM, and RenflexisTM (when the latter 3 are launched)‑may even be considered me-too brands without substantial discounts and without interchangeable designations. Many payers already consider the approved biosimilars as new brands, because they are not inexpensive or interchangeable.
ICER: Current Biologics for Rheumatoid Arthritis Well off the Mark for Cost Effectiveness
which assesses the value of therapies based on effectiveness and cost, found that none of the available immunomodulators approach the cost-effectiveness threshold of $100,000 to $150,000 per quality-adjusted life-year (QALY).